Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes

Plain-language summary

This study examined the outcomes of a therapy using mesenchymal stem cells obtained and expanded from the patient's own bone marrow in people with type 2 diabetes. It enrolled patients aged 18 and older who had had type 2 diabetes for at least 5 years and whose HbA1c was between 7.5% and 9%. The trial was conducted in Phase 1/Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

PHASE1/PHASE2

Status

Completed

Sponsor

Vinmec Research Institute of Stem Cell and Gene Technology

Intervention

Expanded autologous bone marrow-derived mesenchymal stem cell

Start date

11/1/2017

Estimated completion

8/1/2019

Countries

Vietnam

Related genes

Locations

• Hanoi, Vietnam

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Males and females
* Age from 18 years and above.
* Hemoglobin A1c (HbA1c) is ranged from 7.5% to 9% at baseline.
* Type 2 diabetes duration 5 years or more.
* Before the screening, joint or combined with insulin, oral medications to treat more than 3 months.
* Who signed the informed consent form.

Exclusion Criteria:

* Type 1 diabetes.
* Chronic disease or severe disease, including cancer, severe heart disease, kidney disease, liver disease, etc.
* According to the medical doctor's judgement, may endanger the safety of the subjects